Literature DB >> 26235025

Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity.

Mohammed Abdulaziz1, Grant W Mallory1, Mohamad Bydon2, Rafael De la Garza Ramos2, Jason A Ellis3, Nadia N Laack4, W Richard Marsh1, William E Krauss1, George Jallo2, Ziya L Gokaslan2, Michelle J Clarke1.   

Abstract

OBJECT While extent of resection has been shown to correlate with outcomes after myxopapillary ependymoma (MPE) resection, the effect of capsular violation has not been well studied. The role of adjuvant radiation also remains controversial. In this paper the authors' goals were to evaluate outcomes following resection of MPE based on intraoperative capsular violation and to explore the role of adjuvant radiotherapy in cases of capsular violation. METHODS A retrospective review of patients undergoing resection of MPE at 2 academic institutions between 1990 and 2013 was performed. Cases with dissemination at presentation, less than 12 months of follow-up, or incomplete records were excluded. Extent of resection was defined as en bloc if all visible tumor was removed without capsular violation, gross-total resection (GTR) if all visible tumor was removed, but with capsular violation, and subtotal resection (STR) if a known residual was left at the time of surgery. Postoperative MR images were reviewed to confirm the extent of resection. Primary outcomes were progression-free survival (PFS) and overall recurrence rates. The effects of extent of resection, capsular violation, and adjuvant radiotherapy on recurrence rates and PFS were analyzed using Kaplan-Meier statistics. Associations between recurrence and preoperative variables were evaluated using Fisher exact methods and t-tests where appropriate. RESULTS Of the 107 patients reviewed, 58 patients (53% were male) met inclusion criteria. The mean age at surgery was 40.8 years (range 7-68 years). The median follow-up was 51.5 months (range 12-243 months). Extent of resection was defined as en bloc in 46.5% (n = 27), GTR in 34.5% (n = 20), and STR in 18.9% (n = 11). No recurrences were noted in the en bloc group, compared with 15% (n = 3) and 45% (n = 5) in the GTR and STR groups. En bloc resection was achieved most frequently in tumors involving the conus. Twelve patients (20%) underwent adjuvant radiotherapy following either STR or GTR. The overall recurrence rate was 13.8% (n = 8), and the 5-year PFS was 81%. Capsular violation was associated with a higher recurrence rate (p = 0.005). Adjuvant radiotherapy showed a nonsignificant trend of lower recurrence rates (16.7% vs 31.6%, p = 0.43) and longer PFS at 5 years (83.3% vs 49.9%, p = 0.16) in cases of capsular violation. CONCLUSIONS A strong correlation between capsular violation and recurrence was found following removal of MPE and should be assessed when defining extent of resection in future studies. Although the use of adjuvant radiotherapy in cases of capsular violation showed a trend toward improved PFS, further investigation is needed to establish its role as salvage therapy also appears to be effective at halting disease progression.

Entities:  

Keywords:  GTR = gross-total resection; MPE = myxopapillary ependymoma; PFS = progression-free survival; STR = subtotal resection; capsule; myxopapillary ependymoma; radiation therapy; surgery; tumor recurrence

Mesh:

Year:  2015        PMID: 26235025     DOI: 10.3171/2015.5.FOCUS15164

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  19 in total

1.  National trends in management of adult myxopapillary ependymomas.

Authors:  Daphne B Scarpelli; Claire B Turina; Patrick D Kelly; Arpine Khudanyan; Jerry J Jaboin; Shearwood McClelland
Journal:  J Clin Neurosci       Date:  2020-01-24       Impact factor: 1.961

Review 2.  Current and Emerging Methods of Management of Ependymoma.

Authors:  Sebastian M Toescu; Kristian Aquilina
Journal:  Curr Oncol Rep       Date:  2019-07-29       Impact factor: 5.075

Review 3.  Spinal cord ependymoma: a review of the literature and case series of ten patients.

Authors:  Emma Celano; Arsalaan Salehani; James G Malcolm; Erik Reinertsen; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2016-05-06       Impact factor: 4.130

4.  Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes.

Authors:  James E Bates; Gyujae Choi; Michael T Milano
Journal:  J Neurooncol       Date:  2016-06-15       Impact factor: 4.130

Review 5.  Multifocal lumbar myxopapillary ependymoma presenting with drop metastasis: a case report and review of the literature.

Authors:  Joanna K Tabor; Brendan Ryu; Daniel Schneider; Daniel M Sciubba; Ashwatha Narayana; Avraham Zlochower; Randy S D' Amico
Journal:  Spinal Cord Ser Cases       Date:  2022-04-22

Review 6.  EANO guidelines for the diagnosis and treatment of ependymal tumors.

Authors:  Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

7.  Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients.

Authors:  Anne-Sophie Montero; Suzanne Tran; Aymeric Amelot; Félix Berriat; Guillaume Lot; Stephan Gaillard; Chiara Villa; Marc Polivka; Clovis Adam; Ahmed Idbaih; Loïc Feuvret; Alexandre Carpentier; Fabrice Parker; Franck Bielle; Bertrand Mathon
Journal:  J Neurooncol       Date:  2021-02-23       Impact factor: 4.130

Review 8.  Ependymoma: Evaluation and Management Updates.

Authors:  Roberta Rudà; Francesco Bruno; Alessia Pellerino; Riccardo Soffietti
Journal:  Curr Oncol Rep       Date:  2022-04-06       Impact factor: 5.945

9.  Spinal Cord Ependymoma - Surgical Management and Outcome.

Authors:  Wail Mohammed; Michael Farrell; Ciaran Bolger
Journal:  J Neurosci Rural Pract       Date:  2019 Apr-Jun

10.  Surgical Treatment of Intra- and Juxtamedullary Spinal Cord Tumors: A Population Based Observational Cohort Study.

Authors:  Oscar Persson; Alexander Fletcher-Sandersjöö; Gustav Burström; Erik Edström; Adrian Elmi-Terander
Journal:  Front Neurol       Date:  2019-07-26       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.